Trial · NCT03059134
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03059134, Phase 3, Completed, Buddhist Tzu Chi General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan. Trials, record NCT03059134. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03059134
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
- NCT number
- NCT03059134
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 168 participants, actual
- Lead sponsor
- Buddhist Tzu Chi General Hospital
- Conditions
- Urinary Incontinence, Overactive Bladder Syndrome
- Interventions
- Mirabegron 25mg
- First posted
- 2017-02-23
- Last updated
- 2017-02-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction of urgency or urgency incontinence episode by 2 per day | from baseline to 12 weeks | The percentage of patients in each arm who had reduction of urgency or urgency incontinence episode by 2 per day |
| Secondary | International Prostate Symptom Score total (IPSS-T) | from baseline to 12 weeks | The change of the general bladder symptom score |
| Secondary | quality of life (QoL) index | from baseline to 12 weeks | The change of QoL index |
| Secondary | Overactive Bladder Symptom Score (OABSS) | from baseline to 12 weeks | The change of OABSS |
| Secondary | Urgency Severity Scale (USS) | from baseline to 12 weeks | The change of USS |
| Secondary | Patient's Perception of Bladder Condition (PPBC) | from baseline to 12 weeks | The change of PPBC |
| Secondary | Global Response Assessment (GRA) | from baseline to 12 weeks | The change of GRA |
| Secondary | maximum flow rate (Qmax) | from baseline to 12 weeks | The change of Qmax |
| Secondary | voided volume (Vol) | from baseline to 12 weeks | The change of vol |
| Secondary | Postvoid residual volume m(PVR) | from baseline to 12 weeks | The change of PVR |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03059134
GET https://conductscience.org/api/trials/v1/NCT03059134/registered